Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …

Abstract Mutant p53 (mutp53) cancers are surprisingly dependent on their hyperstable
mutp53 protein for survival, identifying mutp53 as a potentially significant clinical target …

Maintenance of normal cell growth and differentiation is highly dependent on coordinated
and tight transcriptional regulation of genes. In cancer, genes encoding growth regulators …

Potentiation of epidermal growth factor receptor (EGFR) inhibitors is required in squamous
cell carcinoma of head and neck (SCCHN) to improve their therapeutic index. We …

As key molecules that drive progression and chemoresistance in gastrointestinal cancers,
epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in …

Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor
suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines …

Breast carcinogenesis is a multistep process involving both genetic and epigenetic changes.
Epigenetics is defined as reversible changes in gene expression, not accompanied by …

Histone deacetylase inhibitors (HDACI) are promising anticancer agents and their use in
combination with conventional anticancer drugs is currently under investigation. We …

[Frontiers in Bioscience 16, 340-359, January 1, 2011] 340 HDACi – going through the
mechanisms Malgorzata Wanczyk1, Katarzyna Page 1 [Frontiers in Bioscience 16, 340-359 …

A Phase I Study of Panobinostat in Combination With Gemcitabine in the Treatment of Solid
Tumors Page 1 Clinical Advances in Hematology & Oncology Volume 9, Issue 3 March 2011 …